2020 Year in Review - AML
Single cord blood transplantation could be an effective treatment option for AML patients aged ≥60 years, but the risks for engraftment failure and early nonrelapse mortality should be considered. Read More ›
Treatment with enasidenib in newly diagnosed patients with IDH2mut acute myeloid leukemia (AML) was associated with low early death and high complete response (CR)/CR with incomplete hematologic recovery rates, and yielded durable remissions. Read More ›
A proof-of-principle study confirmed the benefit of combining large cohorts of data from patients with AML using the HARMONY Alliance platform, thus demonstrating that such “big data” can help inform individualized therapy for optimal clinical outcomes. Read More ›
Data from a larger cohort of patients with AML suggest IDH inhibitors may be of particular interest in older adults and patients aged >60 years, based on co-occurring NPM1 and DNMT3A mutations. Read More ›
A post-hoc analysis of data from the BRIGHT AML 1003 study showed improved overall survival associated with attaining various blood count thresholds after 1 cycle of glasdegib + LDAC versus LDAC alone in patients with newly diagnosed AML. Read More ›
Venetoclax + FLAG-IDA was effective, elicited deep responses, and had an acceptable safety profile across multiple AML subgroups, representing an attractive option for adverse-risk newly diagnosed and relapsed/refractory AML patients, and as a bridge to allo-SCT. Read More ›
An analysis of outcomes for patients with treatment-naïve AML ineligible for intensive chemotherapy receiving either azacitidine or decitabine in the ASTRAL-1 study showed no significant differences in complete response (CR), overall CR, overall survival, or safety. Read More ›
he SAL-DaunoDouble trial interim analysis suggests that, in patients with acute myeloid leukemia (AML) who respond well to a first 7+3 induction cycle of cytarabine plus anthracycline, it may be possible to omit a second induction cycle if deemed high-risk. Read More ›
A retrospective analysis of patients with IDH-mutated AML revealed that NPM1mut is the best prognostic factor in patients who are IDH1mut and IDH2R140mut, making it a useful stratification factor for clinical trials. Read More ›
The efficacy of 10-day decitabine plus venetoclax is comparable to intensive chemotherapy regimens as salvage therapy in younger patients with relapsed/refractory AML, and is an appropriate bridge to allogeneic stem-cell transplantation. Read More ›